Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Analyst firm BofA Securities has lowered its price target on Pfizer to $27.00 from $28.00, maintaining a Neutral rating. This adjustment follows Pfizer’s guidance indicating a faster-than-expected ...

A brief comment about today’s market action is in order before we discuss the featured analyst reports. Stocks appeared immune to the Washington drama for a while, but have started taking note of the ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...

Investing.com - Bernstein SocGen Group has reiterated its Market Perform rating for Pfizer (NYSE:PFE) with a price target of $30.00, closely aligning with InvestingPro’s Fair Value assessment that ...

Pfizer Inc. shares currently offer a dividend yield approaching 7%, ranking among the highest in the S&P 500 index. While the upcoming ex-dividend date of January 23 presents an opportunity for income ...

Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the ...

Shares of Pfizer PFE dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026, which fell short of investor expectations. The company is expected to ...